ClinicalTrials.gg
Enrolling by invitationNCT01758653Updated Sep 29, 2023

Carbon Monoxide Blood and DNA Biorepository

An observational study in Carbon Monoxide Poisoning, sponsored by Intermountain Health Care, Inc.. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Intermountain Health Care, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Carbon Monoxide Poisoning with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Carbon Monoxide Poisoning · United States.

Started
2012
the only one that year
Observational
8 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
Intermountain Health Care, Inc.

Among the 12 studies in Carbon Monoxide Poisoning with a site in United States, this one is the only one that started in 2012, is one of 8 observational ones, and was the 7th registered.

Carbon Monoxide Poisoning

44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.

Browse Carbon Monoxide Poisoning studies →

Open to participants now

2 of the 12 studies in Carbon Monoxide Poisoning with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Carbon Monoxide Poisoning studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carbon Monoxide Poisoning with a site in United States, or all of them as a file.
02

Study summary

The purpose of this biorepository is to collect blood from patients at the time of CO poisoning and at follow-up visits months to years later. These samples can be used in the future to learn more about how CO damages the heart and brain and whether blood tests could predict which patients will have problems after CO poisoning.

Read the detailed description

The investigators propose to establish a biorepository for storage of serum, plasma, and DNA collected from patients with carbon monoxide (CO) poisoning. Participants will also be evaluated for clinical outcome. The biorepository will include serum and plasma from CO-poisoned patients drawn at the time of injury as well as from blood drawn at clinical follow-up visits. The biorepository will also bank DNA from these participants.

These specimens can be analyzed in the future to elucidate potential inflammatory and immunological mechanisms that cause brain and heart damage and identify possible biological and genetic predictors of poor outcome.

03

Conditions studied

  • Carbon Monoxide Poisoning

Keywords

  • CO poisoning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population includes patients who present to LDS Hospital or Intermountain Medical Center with symptomatic carbon monoxide poisoning and documented exposure to carbon monoxide.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic carbon monoxide poisoning (headache, nausea, vomiting, dizziness, fatigue, muscle aches, slowed mentation, confusion, loss of consciousness, etc.).
  2. Documented exposure to carbon monoxide and no other reasonable explanation for their signs and symptoms.

Exclusion criteria

Exclusion criteria:

  1. Pregnancy
  2. Age \< 18 years
  3. Unable to obtain
  4. Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason. The investigator and the Sponsor, prior to enrolling the subject on a case-by-case basis, must approve and document any waiver of these inclusion and exclusion criteria.
  5. Anemia requiring blood products within the last 4 months or hematocrit less than the laboratory normal reference range
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Biorepository

    Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.

    Other: No study intervention

Interventions

  • OtherNo study intervention

    There is no study-related intervention.

06

What researchers measure

Primary outcomes

  1. Biorepository for serum and plasma

    Serum and plasma from blood collected within 24 hours of acute CO poisoning

    Time frame: Within 24 hours of CO Poisoning

Secondary outcomes

  1. Serum and plasma (sub-acute)

    Serum and plasma collected 4 weeks to 4 months after poisoning

    Time frame: 4 weeks to 4 months after CO poisoning

  2. DNA Sequestration

    DNA sequestered from blood drawn up to 1 year from CO poisoning

    Time frame: 24 hours to 12 months after CO poisoning

  3. Serum and plasma (long-term)

    Serum and plasma collected 4 months to 12 months after poisoning

    Time frame: 4 months to 12 months after CO poisoning

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2012 (actual). Primary completion is estimated for Dec 2032, 250 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2012
First posted
Jan 1, 2013
StartActual
Feb 2012
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01758653
Responsible party
Lindell Weaver (Lindell Weaver, MD, Intermountain Health Care, Inc.) — Principal investigator
First posted
Jan 1, 2013
Start date
Feb 2012
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Sep 29, 2023

Study contacts

Lindell K. Weaver, MD
principal investigator · Intermountain Health Care, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion